Want to see SEPN full AI Analyst Report?
SEPN Stock Chart & Stats
$33.10
$0.14(0.42%)
At close: 4:00 PM EDT
$33.10
$0.14(0.42%)
Day’s Range― - ―
52-Week Range$10.74 - $51.10
Previous CloseN/A
Volume33.99K
Average Volume (3M)489.97K
Market Cap
$2.08B
Enterprise Value$1.16K
Total Cash (Recent Filing)$372.32M
Total Debt (Recent Filing)$22.55M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Nov 25, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding46,676,950
10 Day Avg. Volume335,874
30 Day Avg. Volume489,971
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.23
Price to Sales (P/S)26.85
P/FCF Ratio11.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$54.00Price Target Upside63.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.31
Revenue Forecast (FY)$76.95M
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained positive operating and free cash flow in the trailing twelve months materially reduces near-term financing pressure, enabling continued R&D and commercialization spending from internal resources. This cash generation is a durable buffer that supports multi‑period program advancement and optionality without immediate dilution.
Revenue Scale & Gross MarginsRapid revenue scaling to nearly $100M TTM alongside ~72.5% gross margins indicates improving commercial traction and attractive unit economics. High gross margins provide structural leverage to absorb R&D and SG&A while improving the path to operating profitability as top-line growth continues, supporting durable margin sustainability.
Pipeline Clinical Progress (SEP-479)Observed favorable clinical half‑life and progression of SEP‑479 through Phase 1 are structural product-development positives: they de‑risk the program, support once‑daily oral positioning, and justify further investment. Measured clinical progress strengthens the long‑term commercial runway if later‑stage data confirm differentiation.
Bears Say
Ongoing Net LossesDespite improvement, the company remains loss‑making on a trailing twelve‑month basis, reflecting investment‑heavy operations. Persistent net losses mean Septerna must sustain cash generation or access capital to fund development and commercialization, which can pressure returns and create dilution risk if external financing is required.
Cash Flow Durability RiskRecent strong cash flows include elements flagged as potentially non‑recurring; FCF growth ticked down ~1.7% TTM. If the positive cash profile results from timing or one‑off receipts, repeatability is uncertain, which would reintroduce funding needs for R&D and slow conversion of strong gross margins into sustained operating profits.
Low Returns / Investment IntensityNegative returns on equity and ongoing heavy R&D/SG&A spending indicate low capital efficiency. Until operating margins turn positive, high investment intensity will constrain return metrics and lengthen the timeframe to generate equity returns, making long‑term value creation contingent on successful clinical/commercial execution.
Septerna, Inc. News
SEPN FAQ
What was Septerna, Inc.’s price range in the past 12 months?
Septerna, Inc. lowest stock price was $10.74 and its highest was $51.10 in the past 12 months.
What is Septerna, Inc.’s market cap?
Septerna, Inc.’s market cap is $2.08B.
When is Septerna, Inc.’s upcoming earnings report date?
Septerna, Inc.’s upcoming earnings report date is Nov 25, 2026 which is in 101 days.
How were Septerna, Inc.’s earnings last quarter?
Septerna, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.426 by $0.136.
Is Septerna, Inc. overvalued?
According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued.
Does Septerna, Inc. pay dividends?
Septerna, Inc. does not currently pay dividends.
What is Septerna, Inc.’s EPS estimate?
Septerna, Inc.’s EPS estimate is -0.4.
How many shares outstanding does Septerna, Inc. have?
Septerna, Inc. has 46,676,950 shares outstanding.
What happened to Septerna, Inc.’s price movement after its last earnings report?
Septerna, Inc. reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.426. Following the earnings report the stock price went up 22.934%.
Which hedge fund is a major shareholder of Septerna, Inc.?
Currently, no hedge funds are holding shares in SEPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Septerna, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.00 (63.14% Upside)
$54.00 (63.14% Upside)
Blogger Sentiment
Neutral
SEPN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 620.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $63.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 10.5%
Last 30 Days ▲ 10.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.49%
Trailing 12-Months
Company Description
Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
SEPN Stock 12 Month Forecast
Average Price Target
$54.00
▲(63.14% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
―
Ownership Overview
6.12% Insiders
8.46% Mutual Funds
28.12% Other Institutional Investors
50.41% Public Companies and
Individual Investors